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Abstract
Thrombomodulin (TM) is an endothelial glycoprotein that is 
present in all blood vessels. Five percent of all patients with 
atypical hemolytic uremic syndrome (aHUS) have mutations 
in the gene coding for TM, with a peak presentation in young 
children. Mutations often translate into quantitative and 
qualitative abnormalities of this endothelial glycoprotein. 
Outcome of the TM-associated aHUS is relatively poor with 
frequent relapses after transplantation despite its mem-
brane-bound character. We observed a woman presenting 
with malignant hypertension (MHT) and associated kidney, 
brain, cardiac, and hematological involvement with throm-
botic microangiopathy on kidney biopsy. She had a docu-
mented mutation of the gene coding for TM, which was as-
sociated with both aHUS and an increased risk for venous 
and arterial thrombosis. As TM has anti-coagulant, anti-in-
flammatory, and cytoprotective properties and also attenu-
ates alternative complement activation, this glycoprotein 
could play an active role in other diseases with endothelial 
involvement apart from aHUS. We discuss the potential role 
of TM in the pathophysiology of various endotheliopathies 
including MHT. We also provide a framework for future ther-
apeutic options. © 2018 S. Karger AG, Basel
Background
Malignant hypertension (MHT) is a life-threaten-
ing condition classically defined by hypertensive retinop-
athy grade III/IV and/or other end-organ damage, 
while criteria for blood pressure values are inconsistent 
but mostly define diastolic blood pressure ≥120 mm Hg 
[1]. Recent guidelines urge to discriminate between 
 hypertensive emergency and hypertensive urgency. 
 Hypertensive emergency is defined by severe hyperten-
sion (> 180/120 mm Hg) and impairment of at least 3 or-
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gans even without hypertensive retinopathy. It requires 
prompt treatment usually by parenteral drugs, while hy-
pertensive urgency is defined as significantly elevated 
blood pressure without end-organ failure treated by the 
reinstitution or intensification of antihypertensive 
drugs [2]. One in four patients with MHT has biochemi-
cal signs of micro-angiopathic hemolytic anemia. Al-
though thrombotic microangiopathy (TMA), whether or 
not in association with underlying atypical hemolytic 
uremic syndrome (aHUS) can induce severe hyperten-
sion [3], the combined retinal findings of cotton-wool 
spots, flame hemorrhages, retinal arteriolar narrowing, 
and optic disc swelling are still considered to be pathog-
nomonic for MHT. This should prompt immediate and 
aggressive blood pressure lowering and should suffice to 
obtain resolution of TMA and partial or complete recov-
ery of the kidney function without need for additional 
treatment. Increasing evidence points toward pathophys-
iological overlap between clinical conditions that share 
TMA features such as thrombotic thrombocytopenic 
purpura, aHUS, scleroderma with renal crisis, preeclamp-
sia, and even hypertension [3–5]. Although a potential 
role of a disturbed complement system in the pathophys-
iology of hypertension-associated kidney damage is in-
creasingly being considered [6], the exact role of alterna-
tive complement dysregulation in the pathophysiology of 
MHT currently remains ill defined. We describe a patient 
with TMA and acute kidney injury with tentative diagno-
sis of aHUS, which was initially treated with plasmapher-
esis. Ophthalmological examination revealed, however, 
papilledema with lipoid exudates and choroidal hypoper-
fusion suggestive of grade IV hypertensive retinopathy. A 
genetic screening panel for aHUS revealed a very rare 
pathogenic mutation of the gene coding for thrombo-
modulin (TM; c.1502C>T), which has been described as 
a risk factor for aHUS, mainly in children and young 
adults. We discuss the diagnostic dilemmas, which might 
arise in similar clinical situations and speculate on a pos-
sible pathogenetic and therapeutic role of TM in MHT. 
Case Vignette
A 33-year-old woman presented with intermittent 
headache for 6 weeks, and since 1 week palpitations, fa-
tigue, and exertional dyspnea. She had no visual or neu-
rological complaints. Her medical history was blank apart 
from biliary pancreatitis 10 years ago and mild obesity 
without any notion of hypertension. She had 1 pregnancy 
10 years ago, which was uneventful apart from severe 
postnatal anemia without biochemical signs of TMA and 
no need for transfusion. She was not taking any drugs 
apart from intermittent nonsteroidal anti-inflammatory 
drugs and she smoked 2 cigarettes per day. Her blood 
pressure at admission was 205/140 mm Hg, but otherwise 
her clinical examination was unremarkable. She had no 
clinical signs suggestive of systemic sclerosis. Biochemi-
cal evaluation revealed signs of TMA (Table 1). The se-
rum creatinine at admission was 3.2 mg/dL (estimated 
glomerular filtration rate 18 mL/min/1.73 m2) according 
to the chronic kidney disease (CKD)-epidemiology col-
laboration formula with urinalysis showing a blank sedi-
ment but moderate proteinuria (2 g/g creatinine) with al-
buminuria. Coagulation parameters, viral serology, liver 
tests, antiphospholipid antibodies and antinuclear factor, 
and a disintegrin and metalloproteinase with a thrombo-
spondin type 1 motif member 13 (ADAMTS13) were un-
remarkable and ultrasound showed normal-sized kid-
neys without obstruction. Acceptable blood pressure 
control was initially realized upon the initiation of calci-
um antagonists and beta-blockers. A kidney biopsy 
showed overall 12 glomeruli, some of which were slightly 
ischemic (Fig. 1a). Expansion of the mesangial matrix was 
noted with enlargement of the capillary walls by suben-
dothelial expansion. There was scattered mesangiolysis 
and sequestration of erythrocytes and some neutrophils 
in some capillaries (Fig. 1b). There were signs of focal seg-
mental fibrinoid necrosis in some glomeruli with pres-
ence of fragmented erythrocytes (Fig. 1c, d). There was 
mild tubular atrophy with interstitial fibrosis and lym-
phocytic inflammation. Multiple arterial segments had 
intimal expansion, often with preexistent fibrotic intimal 
thickening. On Masson staining, there was fibrinoid ne-
crosis in arterial vessel walls (Fig. 1c, d). Immunofluores-
cence was negative. 
Daily plasma exchange was initiated for assumed 
aHUS with mild signs of TMA. An echocardiography 
showed left ventricular hypertrophy and signs of grade 3 
diastolic dysfunction. Magnetic resonance imaging dem-
onstrated white matter brain lesions. A first ophthalmo-
logical examination demonstrated moderate papillede-
ma with peripapillary exudates (Fig.  2a, b). This was 
 interpreted as a sign of MHT and prompted the discon-
tinuation of plasma exchange and optimization of blood 
pressure control by the initiation of angiotensin-convert-
ing enzyme inhibitors next to moxonidine. A repeated 
fundus examination with additional fluoresceine-angi-
ography and ocular coherence tomography confirmed 
MHT-associated retinopathy with TMA, leakage of the 
disc, delayed choroidal filling, and macular drusenoid 
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Fig. 1. Histological abnormalities on kid-
ney biopsy. a Micro-aneurysm formation 
and basal membrane remodelling in isch-
emic glomerulus (periodic acid shiff). b Fi-
brinoid necrosis and mucinous intima ex-
pansion with the presence of fragmented 
red blood cells obliterating the capillary lu-
men (Masson staining). c Fibrinoid necro-
sis of the vessel wall (Masson staining). 
d Mucinous intima expansion and fibrotic 
thickening (Masson staining).
Table 1. Laboratory values
Test Value Reference value
At presentation Five months after presentation
Haptoglobin, g/L 0.23 1.94 0.3–2.0
Hemoglobin, g/dL 9.6 13.8 11.8–14.8
Thrombocytes, ×103/µL 137 236 171–374
C3, mg/dL 105 157 72–156
C4, mg/dL 39 15–45
LDH, U/L 527 150 105–233
Schistocytes, % 2 Negative
Serum creatinine, mg/dL 3.2 1.8 0.5–0.95
Antinuclear factor Negative
ADAMTS13, % 94.5 50–160
ANCA Negative
C3d, mg/dL 1.4 <1.2
C3d/C3 0.9 <1.4
SC5b-9, ng/mL 136 <314
Factor B, mg/dL 18 8–21
Factor H concentration, mg/dL 82 37–73
Factor H activity, % 91 65–106
Factor I, mg/dL 11.4 4.0–10.7
CD46 (MCP) 99.9% granulocytes 95–100
TM, ng/mL 5.3 1.3–2.5
TAFIa, % 120 40–250
ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13; TAFIa, 
activated thrombin activatable fibrinolysis inhibitor; TM, thrombomodulin.
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Fig. 2. Eye abnormalities. a Right eye composite color fundus pho-
tograph (Topcon Fundus Camera): swollen disc with telangiectatic 
vessels, lipoid exudates surrounding the disc with tendency of star 
formation toward the macula, mildly engorged and tortuous retinal 
veins, small drusenoid deposits in the foveal area. b Left eye poste-
rior pole color fundus photograph: swollen disc with telangiectatic 
vessels, lipoid exudates surrounding the disc with tendency of star 
formation toward the macula, mildly engorged and tortuous retinal 
veins, small drusenoid deposits in the foveal area. c Right eye color 
fundus photograph right eye centred on the optic disc (after 
1 month): decreased edema. d Left eye color fundus photograph left 
eye optic disc detail (after 1 month). e Fluorescein angiography 
(Topcon Fundus Camera): presentation early phase (24 s) fluores-
cein angiography right eye: delayed choriodal filling of temporal 
macular area and posterior mid-periphery, early hyperfluorescence 
optic disc with fine telangiectactic vessels, staining of small drusenoid 
deposits in the foveal area. f Fluorescein angiography: presentation 
late phase (5m17s) fluorescein angiography right eye: hyperfluores-
cence of the optic disc, patchy leakage choroidal vessels, persistent 
staining of small drusenoid deposits in the foveal area without leak-
age. g Ocular coherence tomography (OCT-Heidelberg Spectralis 
OCT). Right eye macula: small drusenoid lesions in the foveal area 
and lipoid exudates temporal of the fovea within the outer plexiform 
and inner nuclear layer. h OCT. Left eye optic disc: swelling optic 
disc and lipoid exudates within the outer plexiform and inner nu-
clear layer on the nasal and temporal side of the disc.
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deposits (Fig. 2c–h). TMA and optic disc edema can be 
secondary to both aHUS and MHT. The small periph-
eral retinal pigment alterations guided toward underly-
ing MHT. A search for secondary causes of hypertension 
(renal artery stenosis, adrenal tumor, Cushing syndrome 
or pheochromocytoma) was negative. A genetic screen-
ing panel for aHUS, which was ordered earlier, revealed 
a pathogenic mutation of the gene coding for TM 
(c.1502C>T). We assayed TM and thrombin activatable 
fibrinolysis inhibitor (TAFIa) quantitatively by enzyme-
linked immunosorbent assay (respectively IMUBIND 
from Sekisui Diagnostics, Japan and Asserachrom TAFI 
from Diagnostica Stago, USA) and evaluated the alterna-
tive complement cascade 5 months after presentation 
considering the initiation of plasmapheresis at presenta-
tion, impeding an early assessment of these parameters. 
Results are summarized in Table 1. Clinical and bio-
chemical signs of TMA resolved 1 week after blood pres-
sure was adequately controlled. Kidney function recov-
ered partially to a serum creatinine of 1.60 mg/dL with-
out proteinuria 20 months after presentation. Blood 
pressure remains adequately controlled on a combina-
tion of 4 different antihypertensive drugs and her head-
ache completely resolved.
TM and Endothelial Dysfunction
TM is a transmembrane type1-glycoprotein, which is 
uniformly expressed on the vascular endothelium [7]. It 
binds to the proinflammatory thrombin thereby enhanc-
ing the catalytic activation of protein C, which exerts an 
anticoagulant function by cleaving factors Va and VIIIa 
and downregulating further thrombin generation. The 
thrombin-TM complex converts through proteolytic 
cleavage the zymogen thrombin – TAFI into an activated 
form (TAFIa), which inhibits fibrinolysis. At the site of 
vascular injury, thrombin forms the fibrin clot. On the 
intact endothelium adjacent to the site of injury, throm-
bin binds to TM. The thrombin/TM complex amplifies 
the activation of protein C and consequently suppresses 
the clotting cascade, preventing excessive fibrin clot for-
mation. Simultaneously, the activation of TAFIa will pro-
tect the clot already formed from premature lysis. Acti-
vated protein C has also anti-inflammatory and cytopro-
tective properties. TAFIa contributes to the 
anti-inflammatory potential of TM trough cleavage of 
anafylatoxins C3a and C5a [7–9]. In vitro, TM binds to 
factor H and C3b and negatively regulates complement 
by accelerating factor I (CFI)-mediated inactivation of 
C3b in the presence of cofactors, thereby attenuating the 
activation of the alternative complement cascade [7, 8]. 
Mutant TM is less effective in enhancing CFI-mediated 
inactivation of C3b [7]. In addition, TM prevents the di-
rect activation of C5 by thrombin. Also, the lectin-like 
domain of TM binds the proinflammatory cytokine high 
mobility group box 1 (HMGB1), the ligand of receptor of 
advanced glycation end-products (RAGE). TM inhibits 
the proinflammatory HMGB1-RAGE axis by cleaving 
HMGB1 into an inactive fraction [10].
In healthy people, plasma concentrations of TM re-
main relatively low. Endothelial damage of whatever ori-
gin results in proteolysis and shedding of TM of the en-
dothelial layers resulting in a 1.5–2 fold rise in plasma TM 
concentration [8]. This phenomenon is observed in vari-
able conditions associated with TMA such as preeclamp-
sia, sepsis, diffuse intravascular coagulation (DIC), Shiga 
toxin-producing E. Coli (STEC)-induced and atypical 
HUS, thrombotic thrombocytopenic purpura, scleroder-
ma-associated pulmonary hypertension, and arterial hy-
pertension [11–16]. Also, we found an increased plasma 
concentration of TM as a result of endothelial damage in 
our hypertensive patient. Paradoxically, higher plasma 
TM concentrations at inception were associated with a 
lower incidence of coronary heart disease and diabetes in 
a cohort of presumed healthy people, implying that its 
soluble form may be vasculoprotective [17, 18]. Instead, 
young patients with diabetes have increased plasma TM 
concentrations compared to patients without diabetes, 
reflecting endothelial damage [19]. Whether a high plas-
ma TM concentration has to be considered vasculopro-
tective or as a sign of endothelial damage should be inter-
preted according to the vascular context and does not re-
flect the amount of TM present on the endothelium itself 
[20]. In healthy individuals, relatively higher plasma con-
centrations of this protective glycoprotein might reflect a 
higher endothelial production and in this situation, a 
high concentration of soluble TM reflects a low pro-
thrombotic state with low risk of first-ever coronary 
events. In disease conditions, a higher or increasing plas-
ma concentration is caused by increased proteolytic ac-
tivity resulting in the cleavage of endothelial TM. In 
pathologic conditions, a high soluble TM may reflect the 
degree of endothelial damage [15, 20]. Impaired kidney 
or hepatic function can further elevate its concentration 
[8]. Simultaneously, conditions that cause endothelial 
stress such as DIC and sepsis, or more specifically expo-
sure to cytokines, endotoxin, human leukocyte antigen 
antibodies, fibroblast growth factor 23, or Shiga toxin 
temporarily decrease the endothelial synthesis and ex-
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pression of membrane-bound TM (Fig. 3, Table 2) [21–
25]. A low endothelial concentration of TM contributes 
to the procoagulant and proinflammatory vascular state 
of these conditions. Single nucleotide polymorphisms of 
TM are associated with decreased endothelial expression 
and/or functional impairment [26]. This condition has 
previously been associated with an increased risk of coro-
nary disease, venous or arterial thrombosis, and fetal loss 
[27–29]. The pleiotropic endothelium-modifying prop-
erties of TM are translated into beneficial effects of re-
combinant human TM in rodent models of endotoxin-
induced pulmonary vascular damage, ischemia-reperfu-
sion kidney or liver injury, preeclampsia, STEC-HUS and 
acute ischemic stroke [30–35]. Of note, statins increase 
the endothelial expression of TM, possibly contributing 
to its beneficial cardiovascular properties [36], and acti-
Fig. 3. The potential role of thrombomodulin (TM) in malignant 
hypertension (MHT) and associated thrombotic micro-angiopa-
thy. TM is an endothelial transmembrane glycoprotein with pos-
sible relevance in MHT. It has an intracellular domain, a trans-
membrane spanning region, a serine/threonine rich domain, 6 epi-
dermal growth factor (EGF)-like repeats and a lectin-like domain. 
The thrombin (IIa)-binding region has been localized to the fifth 
and sixth EGF-like domains, while the fourth EGF-like domain is 
required for protein C binding to the thrombin-TM complex. The 
serine/threonine-rich spacer region is the site of glycosaminogly-
can (GAG) and especially chondroitin sulphate attachment, en-
abling the interaction between TM and factor H, which is a co-
factor for the factor I-mediated cleavage of C3b into inactive frag-
ments (iC3b). TM scavenges thrombin and abrogates all 
procoagulant activities of thrombin by promoting the activation of 
protein C with consecutive anticoagulant and anti-inflammatory 
properties. Activated thrombin activatable fibrinolysis inhibitor 
(TAFIa) stabilizes fibrin clots at intermediate concentrations. 
They can cleave the anaphylatoxins C3a and C5a at their COOH-
terminal arginine residues. The lectin-like domain binds the pro-
inflammatory cytokine high mobility group box 1 (HMGB1), the 
ligand of receptor of advanced glycation end-products (RAGE), 
which is involved in the pathogenesis of hypertension. TM inhibits 
the proinflammatory HMGB1-RAGE axis by cleaving HMGB1 
into an inactive fraction. Environmental triggers that are associ-
ated with endothelial dysfunction decrease the expression of TM 
on endothelial cells. MHT directly or indirectly via oxidative stress 
and hypoxia (due to microvascular thrombosis and increased con-
centration of vasoconstrictors endothelin-1 and angiotensin-II) 
can decrease the expression of TM. Single nucleotide polymor-
phisms in the gene coding for TM can impair both the concentra-
tion and the function of TM by impeding the binding with throm-
bin and impairment of its activation. HLA, human leukocyte anti-
gen; FGF-23, fibroblast growth factor 23; TNF-alpha, tumor 
necrosis factor alpha; PAI-1, plasminogen activator inhibitor-1.
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vation of the vitamin D receptor increases soluble TM in 
CKD patients, which is a possible mechanism whereby 
improvement in endothelial function may favorably im-
pact vascular health in CKD patients [37].
In humans, recombinant human TM is an ap-
proved  treatment for DIC in Japan. Pooled data from 
randomized controlled trials demonstrated that recom-
binant  TM  nonsignificantly improves first-month sur-
vival by 19% in patients with sepsis-induced DIC with-
out excess bleeding risk [38]. In children, it has been suc-
cessfully utilized as adjuvant treatment in children with 
STEC-HUS [39, 40].
TM and aHUS
Missense mutations in the gene coding for TM can 
lead to a diminished ability to protect against activated 
complement, a feature of 5% of the mostly infantile 
aHUS cases [7, 8, 41, 42]. Delvaeye et al. [7] identified 6 
amino acid-changing, heterozygous missense mutations 
of the coding gene in 7 unrelated patients with aHUS. In 
vitro evaluation demonstrated that mutated TM variants 
resulted in the dysregulation and suppressed activation 
of the complement system [7]. A patient with acute TMA 
was recently demonstrated to have a heterozygous muta-
tion of TM (c.1103C>T) with in vitro decreased genera-
tion of TAFIa [43]. In a multicenter, European cohort, 
mutations of genes coding for TM were associated with 
a poor prognosis of aHUS, which was far worse than for 
mutations in the other membrane-bound membrane co-
factor protein [44]. Only a few of the reported aHUS pa-
tients with TM mutations have undergone transplanta-
tions so far. Relapses after transplantation have been ob-
served and are attributed to circulating mutant soluble 
TM, which is less effective in enhancing CFI-mediated 
inactivation of C3b and so activates the complement sys-
tem rather than providing protection [7, 44]. It has been 
suggested that endothelial TM is downregulated in kid-
ney allografts, with loss of the anti-complement activity, 
thus resulting in a greater dependence on the soluble 
plasma forms of TM for kidney protection. The mutant 
forms of soluble TM may be quantitative or qualitative, 
inadequate to provide sufficient protection or may even 
contribute to disease [45]. The protective role of soluble 
TM so far is unestablished. Also, taking into account that 
about 50% of all aHUS patients have no proven mutation 
in proteins involved in the complement pathway [45], 
possibly some of the patients with aHUS and TM muta-
tion have another unidentified genetic abnormality, 
which promotes the development of aHUS and potential 
relapses after transplantation [46].
TM in MHT
A potential role of TM in MHT has so far not been 
considered. There are however arguments for such a hy-
pothesis. Endothelial dysfunction is a prime mechanism 
leading to hypertension. As TM is a key player in endo-
thelial homeostasis, it is well conceivable that a dysfunc-
tional TM can mediate hypertension. Simultaneously, 
TM is a biomarker of endothelial dysfunction, and hyper-
tension can induce itself endothelial damage. As a hall-
mark of these links, plasma TM concentrations are sig-
nificantly higher in people with hypertension or pregnant 
women with preeclampsia than in control subjects [6]. 
The placental expression of TM was lowest in those 
preeclamptic women with the highest diastolic blood 
pressure [23]. Patients with MHT have abnormalities of 
microvascular function including increased circulating 
endothelial cells and endothelial progenitor cells [47].
The missense mutation with C/T substitution at posi-
tion 1,502, which predicts an amino acid change 
 (Pro483Leu) in the Ser/Thr rich region of TM as observed 
in our patient was both associated with aHUS and an in-
creased propensity toward arterial and venous thrombo-
sis and fetal loss [48]. This mutation is associated with a 
decreased expression and impaired functionality of TM 
[26]. The serine/threonine domain is the site of chon-
droitin sulfate attachment, whose presence not only en-
hances the TM interaction with thrombin, procuring an-
ticoagulant properties, but also binds factor H, while the 
Table 2. TM concentration in different endotheliopathies
Plasma TM Endothelial TM References
Preeclampsia ↑ ↓ [11, 23, 24]
Hypertension ↑ ↓ [15, 16, 24]
aHUS ↑ ↓ [13, 23]
STEC HUS ↑ ↓ [13, 23]
Systemic sclerosis ↑ ? [14]
TTP ↑ ? [13]
Sepsis ↑ ↓ [12, 25]
DIC ↑ ↓ [12, 13, 25]
TM, thrombomodulin; aHUS, atypical hemolytic uremic syn-
drome; TTP, thrombotic thrombocytopenic purpura; DIC, diffuse 
intravasal coagulation; STEC, shiga toxin-producing E. Coli.
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lectin-like domains have an anti-inflammatory potential. 
Alterations of complement activation are mainly caused 
by mutations in the lectin-like domain, whereas muta-
tions in the epidermal growth-factor repeats interfere 
with thrombin-mediated activation of protein C, which 
has anticoagulant and cytoprotective properties, and the 
generation of activated TAFI, which has C3a- and C5a-
degrading properties [8]. Decreased anticoagulant prop-
erties could aggravate microvascular thrombosis in 
MHT.
In retinal endothelial cells, continuous laminar shear 
stress upregulates the expression of TM in a time- and 
dose-dependent manner [49]. Some studies have non-
consistently shown decreased endothelial TM expression 
upon cyclic strain [8]. In conditions of exaggerated shear 
stress, such as in MHT, it is conceivable that retinal dam-
age is more pronounced because endothelial upregula-
tion of TM becomes exhausted, which will manifest more 
rapidly when TM function is impaired due to a genetic 
mutation. Of note, hypertensive retinal endothelial dam-
age (sclerosis) has been associated with increased concen-
trations of plasma TM [15]. 
MHT is characterized by increased concentrations of 
potent vasoconstrictors endothelin-1 and angiotensin-II, 
which together with ongoing platelet aggregation and mi-
crovascular thrombosis can contribute to ischemia and 
hypoxia [50]. Hypoxia has been previously demonstrated 
to downregulate the expression of TM on endothelial 
cells with stable soluble TM concentrations [51]. TM also 
inactivates the proinflammatory cytokine HMGB1, the 
ligand of RAGE, which is involved in the pathophysiol-
ogy of hypertension [52].
Finally, in humans with high blood pressure, the pro-
inflammatory anaphylatoxin C5a plasma concentrations 
are increased [6]. TM inhibits the activation of C5a [8]. 
In animal models of hypertensive kidney damage, C5a 
exerts negative effects on the kidney by binding to C5aR1 
receptors [6]. A dysfunctional TM will be less able of at-
tenuating the damaging effects of C5 on the kidney. It is 
thus plausible that a dysfunctional or decreased concen-
tration of the ubiquitous TM in many different ways con-
tributes to the phenotype of MHT with TMA, renal dis-
ease, retinopathy, myocardial involvement, and white 
matter brain lesions. 
Considering the omnipresence of TM across the vas-
culature, its role in endothelial homeostasis, and its asso-
ciation with different clinical entities that share vascular 
thrombosis, it seems likely that abnormalities in this gly-
coprotein might also translate into many diseases apart 
from aHUS [53].
The aHUS-MHT Conundrum
In practice it is often difficult to distinguish MHT-asso-
ciated TMA from complement-mediated TMA with asso-
ciated severe hypertension, as the latter may well represent 
aHUS [3]. Moreover, in most algorithms of the approach 
of aHUS, the differentiation with MHT is poorly delineat-
ed and guidelines are lacking as to how to diagnose and 
treat patients presenting with MHT-associated TMA. A 
kidney biopsy should be performed only upon achieve-
ment of adequate blood pressure control. It has a rather 
poor discriminatory capacity to disclose the primary etiol-
ogy of renal TMA. Whereas HUS predominantly affects 
the glomeruli, MHT more typically affects arterioles and 
interlobular arteries. Renal TMA is characterized by arte-
riolar and/or glomerular intra-capillary thrombosis, often 
with accumulation of fragmented erythrocytes, and focally 
ischemic or congested glomerular tufts [54]. A kidney bi-
opsy may be informative by distinguishing between low 
versus high probability of aHUS in patients with severe hy-
pertension [3, 55]. Glomerular involvement and identifi-
able fibrin thrombi might increase the likelihood of aHUS 
following 2 recent observational studies [3, 55]. Unfortu-
nately, the included patients mostly had neither MHT nor 
hematological abnormalities suggestive of TMA. If pa-
tients with severe hypertension without evidence of reti-
nopathy grade III/IV have signs of TMA on kidney biopsy 
including glomerular involvement, this increases the odds 
of complement-mediated injury. Screening for comple-
ment abnormalities or TM mutations in all patients with 
severe hypertension presenting with renal TMA might 
however lead to diagnostic overuse of expensive comple-
ment assays, genetic analyses, and unneeded or undirected 
treatments such as plasmapheresis or eculizumab.
In our opinion, an eye fundus examination at presen-
tation remains warranted for patients who present with 
TMA and severe hypertension with or without visual dis-
turbances. However, if the fundoscopy reveals a grade III/
IV retinopathy, then we suggest that treatment with anti-
hypertensive medication instead of immediate plasma-
pheresis be started. While previously ophthalmologic 
findings suggestive of severe hypertensive retinopathy 
precluded further investigations, nowadays, much atten-
tion is paid to masked aHUS presenting with severe hy-
pertension [3]. Most clinical guidelines propose to start 
treatment with plasmapheresis awaiting the results of a 
genetic screening [56–58]. But if antihypertensive treat-
ment results in a complete remission of TMA with recov-
ery of kidney function, genetic screening for aHUS might 
not be indicated. However, in young patients, relapse 
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TMA, inadequate response upon antihypertensive drugs 
or signs of glomerular involvement, and fibrin thrombi 
on renal biopsy, complement and genetic screening in-
cluding genotyping of TM have to be performed (Fig. 4).
Our patient presented with signs of TMA and a hyper-
tensive emergency. An immediate fundoscopy at admis-
sion could have prevented the initiation of plasma ex-
change with its ensuing risks and costs. Considering the 
tentative diagnosis of aHUS, we performed a genetic anal-
ysis in our patient, which revealed a TM mutation. Ag-
gressive management of the blood pressure nevertheless 
easily resolved the biochemical signs of TMA with partial 
restoration of kidney function.
The recognition of the TM mutation in our patient did 
not alter therapy. It is however likely that qualitative de-
fects of TM decrease the ability of the endothelium to re-
cover from complement-driven damage from whatever 
origin, rather than being the prime culprit. A further ex-
ploration of the contribution of a dysfunctional TM in the 
pathophysiology of MHT-related TMA is desirable.
Is There a Therapeutic Role for TM?
A potential therapeutic role of recombinant thrombo-
modulin in the management of MHT-associated TMA can 
be speculated. As the prevalence of TMA associated with 
MHT is 10 times more frequent than that of aHUS, this 
question deserves further attention [1]. TM has shown 
promising results in the treatment approach of DIC, with a 
good safety profile with less bleeding complications in com-
parison with recombinant human activated protein C [38, 
53]. Possibly, the presented case history can set the stage for 
designing not only the diagnostic but also the therapeutic 
Thrombotic micro-angiopathy with severe
hypertension (DBP ≥120 mm Hg)
Exclude other organ damage (perform eye
fundus ± echocardiography/brain MRI)
No abnormalities
Perform complement
assay and genetic
screening including
thrombomodulin
Start plasma exchange and consider
complement-directed treatment (even
before results genetic testing)
blood pressure lowering
Consider aHUS
Hypertensive end-organ damage
Blood pressure lowering (initially IV drugs)
Resolution of TMA/kidney
dysfunction
Conservative approach and
exclude secondary hypertension
No resolution of TMA/kidney dysfunction
over respectively days/weeks and
especially if
- Patients <40 years old
- Glomerular involvement and fibrin thrombi
 on kidney biopsy
- No improvement of blood pressure control
- Relapse TMA
Fig. 4. Algorithm thrombotic microangiopathy (TMA)-Hyperten-
sion. When patients present with signs of TMA and severe hyper-
tension (DBP ≥120 mm Hg), end-organ damage has to be exclud-
ed by an eye fundus, brain MRI, and/or echocardiography. If fun-
doscopy reveals grade III/IV retinopathy or in case of other 
end-organ damage, IV antihypertensive treatment has to be start-
ed. If antihypertensive treatment results in a complete remission 
of TMA with recovery of kidney function, genetic screening for 
atypical hemolytic uremic syndrome (aHUS) might not be indi-
cated. However, if recovery is absent and especially in young pa-
tients, relapsing TMA, inadequate response upon antihypertensive 
drugs, or signs of glomerular involvement and fibrin thrombi on 
renal biopsy, complement and genetic screening including geno-
typing of thrombomodulin (TM) is warranted. If end-organ dam-
age is excluded, then aHUS has to be considered and genetic 
screening for aHUS including TM has to be performed. DBP, dia-
stolic blood pressure; MRI, magnetic resonance imaging.
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